Special Report Download

The Comparative Safety of Type 2 Diabetes Medications: An Analysis Utilizing AdverseEvents Explorer

Type 2 Diabetes Medication Safety Profile Download Special Report: Examining the Comparative Safety of Type 2 Diabetes Drugs to:

  • Review the clinical and post-approval safety information available for Type 2 Diabetes Drugs, using data obtained via Freedom of Information Act (FOIA) requests through March 28, 2014
  • Assess comparative safety research within, and across, classes of drugs
  • Make conclusions on the safety risk of these drugs utilizing RxFilter®, RxSignal®, and RxScore® analytics

Drugs included in the analysis are:

  • GLP-1 Agonists
    • exenatide long acting release (Bydureon; AstraZeneca and Bristol-Myers Squibb)
    • exenatide (Byetta; AstraZeneca and Bristol-Myers Squibb)
    • liraglutide (Victoza; Novo Nordisk)
  • DPP-4 Inhibitors
    • sitagliptin metformin (Janumet; Merck)
    • sitagliptin (Januvia; Merck)
    • linagliptin metformin (Jentadueto; Boehringer Ingelheim and Eli Lilly)
    • alogliptin (Nesina; Takeda)saxagliptin (Onglyza; AstraZeneca and Bristol-Myers Squibb)
    • linaglipitin (Tradjenta; Boehringer Ingelheim and Eli Lilly)
  • SGLT-2 Inhibitors
    • dapagliflozin (Farxiga; AstraZeneca and Bristol-Myers Squibb)
    • canagliflozin (Invokana; Johnson & Johnson)

...For full access to this free report, fill out the form